With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34946-82-2,Copper(II) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.
General procedure: To a 50 mL Schlenk flask, 200 mg (0.35 mmol) H4L2, 310 mg(0.86 mmol) of Cu(OTf)2, and 20 mL of dry CH3CN were added and theresulting mixture allowed to stir for 10 min. To the suspension, 1.0 mLof a 2.18M solution of NMe4OH in MeOH was added, resulting in acolor change to a deep green. After stirring for 1 h, solvent was removedunder vacuum to bring the volume to?5 mL. Diethyl ether (20 mL)was added, resulting in the precipitation of green powder that wascollected by filtration, washed with Et2O (2 x 20 mL) and allowed to dry(96 mg, 33%). Crystals were obtained by addition of KOTf to the CH3CNsolution. Repeated attempts to obtain accurate and reproducible CHNanalysis for K(THF)[L2Cu2(CH3CONH)] and the following complexeswere unsuccessful, which we attribute to incomplete combustion., 34946-82-2
34946-82-2 Copper(II) trifluoromethanesulfonate 2734996, acopper-catalyst compound, is more and more widely used in various fields.
Reference£º
Article; Elwell, Courtney E.; Neisen, Benjamin D.; Tolman, William B.; Inorganica Chimica Acta; vol. 485; (2019); p. 131 – 139;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”